| 1-8 | Acyclovir |
| 10-9 | Amdinocillin (serum bactericidal titer) |
| 100-8 | Cefoperazone (minimum inhibitory concentration (mic)) |
| 1000-9 | DBG Ab from Blood product unit (qualitative) |
| 10000-8 | R wave duration in lead AVR |
| 100000-9 | Health informatics pioneer and the father of LOINC |
| 100001-7 | Health informatics pioneer and cofounder of LOINC |
| 100002-5 | Specimen care is maintained (qualitative) |
| 100003-3 | Team communication is maintained throughout care (qualitative) |
| 100004-1 | Demonstrates knowledge of the expected psychosocial responses to the procedure (qualitative) |
| 100005-8 | Demonstrates knowledge of nutritional management related to the procedure (qualitative) |
| 100006-6 | Demonstrates knowledge of medication management (qualitative) |
| 100007-4 | Demonstrates knowledge of pain management (qualitative) |
| 100008-2 | Demonstrates knowledge of wound management (qualitative) |
| 100009-0 | Demonstrates knowledge of the procedure and expected results (qualitative) |
| 10001-6 | R wave duration in lead I |
| 100010-8 | No injury related to procedure equipment, medical supplies, or instrumentation (qualitative) |
| 100011-6 | No injury related to an electrical source (qualitative) |
| 100012-4 | Participates in decisions affecting the patient's plan of care (qualitative) |
| 100013-2 | Participates in the discharge process (qualitative) |
| 100014-0 | Psychosocial health is maintained at or improved from baseline (qualitative) |
| 100015-7 | No injury related to positioning due to care or procedure (qualitative) |
| 100016-5 | No injury related to a laser source (qualitative) |
| 100017-3 | Perioperative nursing data set outcomes panel |
| 100018-1 | Hospice care Note |
| 100019-9 | ALK gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 10002-4 | R wave duration in lead II |
| 100020-7 | GNA11 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100021-5 | GNAQ gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100022-3 | IDH1 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100023-1 | IDH2 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100024-9 | SETBP1 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100025-6 | SRSF2 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100026-4 | MET gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100027-2 | SMAD4 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100028-0 | FBXW7 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100029-8 | Cancer related multigene analysis cell-free DNA (molecular genetics method) |
| 10003-2 | R wave duration in lead III |
| 100030-6 | Axis I: Temporal aspects score |
| 100031-4 | Axis II: Spatial aspects score |
| 100032-2 | Axis III: Drug taking behavior score |
| 100033-0 | Axis IV: Utilization of the health care system score |
| 100034-8 | Provider of automated external defibrillator use |
| 100035-5 | Exam finding location of Chest |
| 100036-3 | Exam finding location of Lung |
| 100037-1 | Patient contact disposition EMS unit |
| 100038-9 | Patient evaluation disposition EMS unit |
| 100039-7 | Crew disposition for patient care EMS unit |
| 10004-0 | R wave duration in lead V1 |
| 100040-5 | Patient transport disposition EMS unit |
| 100041-3 | Aminoglycoside |
| 100042-1 | Atovaquone |
| 100043-9 | Azithromycin+Ethambutol |
| 100044-7 | Cefcapene |
| 100045-4 | Cefozopran |
| 100046-2 | Cefquinome |
| 100047-0 | Cefteram |
| 100048-8 | Clarithromycin+Ethambutol |
| 100049-6 | Eravacycline |
| 10005-7 | R wave duration in lead V2 |
| 100050-4 | Erythromycin+Ethambutol |
| 100051-2 | Ethambutol+rifAMPin |
| 100052-0 | Flomoxef |
| 100053-8 | Fluoroquinolone |
| 100054-6 | Gamithromycin |
| 100055-3 | Optochin |
| 100056-1 | Panipenem |
| 100057-9 | Prothionamide |
| 100058-7 | Prulifloxacin |
| 100059-5 | Rifapentine |
| 10006-5 | R wave duration in lead V3 |
| 100060-3 | Tildipirosin |
| 100061-1 | Tosufloxacin |
| 100062-9 | Standard Dermatology Outcome Measures panel |
| 100063-7 | Primary skin concern |
| 100065-2 | Satisfied with treatment (qualitative) |
| 100066-0 | Specular microscopy panel |
| 100067-8 | Eye Image magnification |
| 100068-6 | Right eye Fixation point |
| 100069-4 | Left eye Fixation point |
| 10007-3 | R wave duration in lead V4 |
| 100070-2 | Right cornea Cell density |
| 100071-0 | Left cornea Cell density |
| 100072-8 | Right cornea Coefficient of variation |
| 100073-6 | Left cornea Coefficient of variation |
| 100074-4 | Right cornea Hexagonality |
| 100075-1 | Left cornea Hexagonality |
| 100076-9 | Right cornea Endothelial cells counted |
| 100077-7 | Left cornea Endothelial cells counted |
| 100078-5 | Right cornea Endothelial cell area.min |
| 100079-3 | Left cornea Endothelial cell area.min |
| 10008-1 | R wave duration in lead V5 |
| 100080-1 | Right cornea Endothelial cell area.max |
| 100081-9 | Left cornea Endothelial cell area.max |
| 100082-7 | Right cornea Endothelial cell area.mean |
| 100083-5 | Left cornea Endothelial cell area.mean |
| 100084-3 | Right cornea Cell area.standard deviation |
| 100085-0 | Left cornea Cell area.standard deviation |
| 100086-8 | Right cornea Type of Analysis method (specular microscopy) |
| 100087-6 | Toxocara canis 24-35kD IgG Ab (qualitative, immunoblot) |